<DOC>
	<DOCNO>NCT01615757</DOCNO>
	<brief_summary>The study conduct Department Medical Oncology Department Haematology , AIIMS , Delhi . A total 180 patient Acute Myeloid Leukemia complete remission induction chemotherapy enrol study randomize two study arm . ARM- A receive Ara-c 18 gm /m2 3 cycle ARM -B receive Ara-c 12 gm/m2 3 cycle accord study protocol . Aim study compare efficacy two dos term relapse free survival overall survival well time relapse toxicity /treatment related morbidity .</brief_summary>
	<brief_title>Safety Efficacy Study Ara-c 18 gm/m2 Versus 12 gm/m2 3 Cycles Each AML Consolidation</brief_title>
	<detailed_description>Objectives - To compare efficacy two different dos Cytarabine consolidation therapy newly diagnose patient Non APML - Acute Myeloid Leukemia CR post induction - To compare toxicity two different Cytarabine dose Primary end point - Relapse free survival 1 yr randomization - Relapse define &gt; 5 % leukemic blast marrow aspirate new extramedullary disease anytime randomization Secondary end point - Overall survival - Median time relapse - Toxicity- Haematological Non -Haematological Inclusion criterion - Confirmation Acute Myeloid Leukemia morphologic , immunophenotypic analysis - Suitable HIDAC consolidation - AML underlie MDS include Exclusion criterion - Previous AML chemotherapy [ Hydroxyurea - exclusion . ] - CML-BC - Concurrent active malignancy - HIV infection , Uncontrolled Hepatitis B/C - Patients consider upfront PBSCT ( completion CONSOLIDATION ) - Serum Bilirubin &gt; 2 - APML - Delayed recovery blood count /persistent active infection &gt; 45 day start induction - Patients receive reinduction HIDAC - Therapy related AML Methodology - The period enrollment July 1 , 2012 September 30 ,2013 - Baseline information record preformulated proforma design analysis later date Treatment - Standard 3 + 7 INDUCTION Daunomycin Cytarabine DNR 60- 90 mg/m2 per PS comorbidities/active infection presentation - Bone marrow examination - D+ 28 induction earlier need . Patients CR - reinduction regimen per discretion treat physician - Patients complete morphological remission ( 1 2 induction ) : receive consolidation HIDAC randomize two study arm write Informed Consent : Arm A B 90 patient arm Arm A receive HIDAC 18 gm/m2/cycle 3 cycle , i.e . 3 gm/m2 BD , Day 1,3,5 Arm B receive HIDAC 12 gm/m2/cycle 3 cycle , i.e . 2 gm/m2 BD , Day 1,3,5 sample size - Assuming RFS 60 % 1 yr arm keep non-inferiority margin 20 % , Alpha 5 % ,75 patient require arm basis statistical calculation . - 15 patient added arm account loss - Total required arm = 90 - ANC &gt; 1000 , Platelet count &gt; 1 lac require start HIDAC - Detailed information course chemotherapy cycle record including- 1. toxicity 2. detail antimicrobial 3. supportive care ( include transfusion ) 4 . Use growth factor - Cytogenetic analysis use standard technique chromosomal band - Molecular analysis mutation FLT3-ITD perform - Risk stratification do per guideline - Patients arm keep close follow assess blood count /PS , 2 monthly / earlier clinically indicated Statistical Analysis - Qualitative data analyze use Chi-square test - Quantitative data compare use t-test /Mann Whitney test - Besides survival analysis carry .</detailed_description>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<criteria>Confirmation Acute Myeloid Leukemia morphologic , immunophenotypic analysis Suitable HIDAC consolidation AML underlie MDS include Previous AML chemotherapy [ Hydroxyurea exclusion . ] CMLBC Concurrent active malignancy HIV infection , Uncontrolled Hepatitis B/C Patients consider upfront PBSCT ( completion CONSOLIDATION ) Serum Bilirubin &gt; 2 APML Delayed recovery blood count /persistent active infection &gt; 45 day start induction Patients receive reinduction HIDAC Therapy relate AML</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>AML</keyword>
	<keyword>Acute Myeloid Leukemia</keyword>
	<keyword>Cytarabine dose</keyword>
	<keyword>Ara-c dose</keyword>
	<keyword>Consolidation</keyword>
</DOC>